Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A cancer vaccine just cleared a major hurdle in AML. The phase 3 REGAL trial found that galinpepimut-S (GPS) extended median overall survival to 24 months versus 14.7 months with standard treatment in transplant-ineligible AML patients in second or later remission. The drug maker is now gearing up for an FDA biologics license application, with submission expected in early 2027.
A cancer vaccine just delivered a landmark win for one of leukemia's toughest patient populations. The phase 3 REGAL trial showed that galinpepimut-S (GPS), an investigational peptide vaccine targeting the WT1 protein overexpressed in leukemic blasts, significantly improved overall survival in transplant-ineligible AML patients who had achieved a second or later remission — a group with very few effective options.
GPS works by combining four WT1-derived peptides designed to activate both CD8+ and CD4+ T cells, generating a broad antileukemic immune response aimed at eliminating residual disease after remission. It was administered subcutaneously alongside an adjuvant and sargramostim, with most side effects limited to mild injection-site reactions.
By the Numbers:
Why it matters: AML patients who relapse after initial therapy and can't undergo a stem cell transplant have extremely limited options. A survival benefit of nearly 10 months from a well-tolerated immunotherapy vaccine could be a genuine paradigm shift for this high-risk population.